Revolutionizing Cancer Treatment
OncoVation: Innovating Gene Therapy for Pancreatic Cancer
❏ OncoVation is developing an innovative gene therapy platform to disrupt the existing treatment paradigm for the world’s most devastating cancers.
❏ Proprietary therapeutic approach aims to restore the critical WWOX tumor suppressor gene, frequently inactivated in various forms of cancer such as pancreatic cancer and breast cancer.
❏ Compelling preliminary preclinical data demonstrates significant potential for tumor volume reduction and increased survival rate along with the potential to greatly increase potency of ongoing chemotherapy.
❏ Experienced Executive Management team has been assembled in partnership with the Hebrew University of Jerusalem to develop OCV-001 and its gene therapy platform to the clinic.
❏ OncoVation Therapeutics is raising a Seed Round investment to advance its groundbreaking WWOX gene therapy for pancreatic cancer (PDAC) towards an Investigational New Drug (IND) application.
❏ This investment will fund critical validation studies, further validate preclinical results, optimize delivery systems and prepare for scale-up and optimization of the clinical batch manufacturing process.
About OncoVation
OncoVation's WWOX Gene Therapy for Pancreatic Cancer
OncoVation Therapeutics presents a groundbreaking opportunity in a novel gene therapy targeting the WWOX tumor suppressor for pancreatic cancer treatment. Preliminary preclinical studies in murine models, including the highly clinically relevant KWC (KrasG12D/+; Wwoxf/f; Ptf1a-Cre) humanized model, have yielded compelling results, demonstrating the potential of this therapy to revolutionize pancreatic cancer outcomes. We are currently raising investment to conduct further validation studies and advance this program towards Investigational New Drug (IND) application, leveraging the expertise of a leading gene therapy regulatory firm to navigate the evolving regulatory landscape.
Our novel target: WWOX is a critical tumor suppressor gene that is frequently inactivated in pancreatic cancers.2 Extensive research has validated WWOX as a key regulator of tumor growth, and restoring its function has shown remarkable promise in patient-derived xenograft cells and preclinical models. Importantly, our preliminary studies have demonstrated compelling efficacy in a novel KWC mouse model and the known KPC-derived orthotopic model, a gold-standard humanized model that closely mimics human pancreatic cancer. This significantly enhances the translatability and clinical relevance of our findings, providing a strong foundation for further validation.
OncoVation's WWOX Gene Therapy:
A Paradigm Shift: OncoVation Therapeutics is pioneering a cutting-edge gene therapy approach to restore WWOX function in pancreatic cancer cells. Our innovative dual delivery system utilizes:
● mRNA-loaded lipid nanoparticles (LNPs): Enables rapid and efficient delivery of WWOX mRNA, triggering immediate restoration of tumor suppressor activity.
● Adeno-associated virus serotype 9 (AAV9) vectors: Provides sustained WWOX expression, ensuring durable therapeutic effects.This synergistic approach offers a distinct advantage over traditional gene therapies, potentially achieving both rapid onset and long-lasting tumor suppression.
About OncoVation
Innovative Gene Therapies for a Healthier Future
oncoVation is at the vanguard of biotechnology, specializing in the development of advanced gene therapies aimed at treating various forms of cancer, with a focus pn pancreatic cancer. Our mission is to harness the power of genetic engineering to create targeted, effective treatments that improve patient outcomes and quality of life. Through rigorous research and collaboration with leading scientists, we are committed to delivering groundbreaking therapies that address unmet medical needs.
Our team of experts works tirelessly to push the boundaries of what is possible in cancer treatment. By focusing on precision medicine and personalized approaches, we aim to provide patients with therapies that are not only innovative but also tailored to their unique genetic profiles. At OncoVation, we believe in a future where cancer is not just treatable, but curable.
OncoVation Cancer Gene Therapeutics
We have Compelling Preliminary Data: Our preliminary studies in the KWC model have shown promising results, with trends towards significant reduction in tumor volume and increased survival. Further validation studies will solidify these findings and provide robust evidence for IND application.
Targeted Delivery
Our dual delivery system ensures precise targeting of WWOX to pancreatic cancer cells, minimizing off-target effects and maximizing therapeutic efficacy
KPC Model Validation
Demonstrated efficacy in KPC models, the most clinically relevant humanized model of pancreatic cancer, significantly strengthens the translational potential of our approach
World-Class Team
Our team comprises renowned experts in gene therapy and oncology, including Professor Rami Aqeilan, a pioneer in WWOX research, and seasoned industry veterans with a proven track record of success
Meet Our Leadership Team
Our Dedicated Team
Mahmoud El-khateeb, Ph.D.
Chief Executive Officer
Jeff Spitzner, Ph.D.
Chief Development Officer
Anthony Franco
Chief Operations Officer
Rami Aqeilan, Ph.D.
Chief Science Officer